Part 01 · The Question→Part 02 · The Record→Part 03 · The File
← Part 01
Inspection Case File · CF09 · Part 02 of 03

The five fields the FDA investigator expects to find — and the one most files don't have.

A deviation closure with a signature is not the same as a deviation closure with a documented decision. The investigator can tell the difference in thirty seconds.

See the Complete File → Free to read. Buy decision is on the next page.
What separates a decision from a signature

A signature on a CAPA closure form proves that a person signed. It does not prove what they decided.

Under inspection, a signature is evidence of an event. It is not evidence of a decision. The investigator does not doubt the signature. She doubts that anything was decided.

An authorization record is structured to be evidence of a decision. It names the person, the moment, the evidence reviewed, the alternatives evaluated, and the basis on which the conclusion was reached. The investigator does not have to ask the QA Director what she was thinking. The record answers.

Investigator
"Who authorized the conclusion that the out-of-trend stability result did not impact product quality or shelf life, on what evidence, and how was that determination justified at the moment of decision?"
This is the question that requires Field 03 of the authorization record to exist.
The Authorization Record · Required Structure

Five fields. Missing any one is the gap a 483 cites.

Every authorization record for a deviation root cause conclusion must contain the following five fields. The third field is the one that is almost always missing.

  1. 01
    The conclusion being authorized
    Stated as a decision, not a description. Not "no impact." Specifically: the conclusion that the 1.8% downward assay trend at 18 months reflects analytical variability and not true product degradation, on the basis of historical method variability characterization, trend rate projection against shelf-life specification, and risk evaluation supporting acceptance of residual shelf-life risk.
  2. 02
    The analytical evidence reviewed at authorization
    Method validation variability data. Historical assay results across multiple lots and timepoints. The trend rate projection. The shelf-life specification limit. The current and remaining timepoints in the protocol.
  3. 03
    Alternative explanations evaluated and rejectedMost Often Missing
    The candidate causes of the trend considered before analytical variability was concluded. Not "we considered alternatives." The actual alternatives — early-stage degradation pattern, packaging integrity issue, container-closure compromise, formulation drift — and the documented basis on which each was eliminated. This is the section a 483 cites when it is missing.
  4. 04
    The risk evaluation applied
    What was at stake if the no-impact conclusion was wrong. Patient impact from product reaching market with insufficient remaining shelf life.
  5. 05
    The named decision owner and timestamp
    The individual whose authority basis is documented. Not the Stability Manager signature. The person who reviewed the analytical evidence, evaluated the alternative explanations, applied the risk standard, and authorized the conclusion.
Why Field 03 matters most

A deviation file almost never contains a documented alternative-causes evaluation. The investigator opens to it first.

Most deviation investigations conclude with a single root cause. They rarely document the alternatives that were evaluated and eliminated to arrive there. The investigator knows this. It is the field she opens to first.

If field 03 is empty, every other field is suspect. The evidence in field 02 may have been reviewed, but no alternative interpretations are on record. The conclusion in field 01 may be correct, but the reasoning is unreconstructable. The signature in field 05 attests to the conclusion, not to the analysis that produced it.

An authorization record without a documented alternative-causes evaluation is not an authorization record. It is a signature on a conclusion.

Why this matters now

The five-field structure is the same whether the inspection is this quarter or next year. The difference is whether you build the record now — when you have time, evidence, and the original decision-maker available — or under inspection pressure when none of those are guaranteed.

Reference Example

DDR-OOT-001 — Pantoprazole Sodium DR Tablets 40 mg — Stability OOT-2024-0019

The same scenario from Part 01, with the authorization record that should have existed in the file. Excerpt from the complete reference DDR.

Decision Defense Record · DDR-OOT-001 · Excerpt
Stability OOT Disposition — OOT-2024-0019
Decision Authorized
The conclusion that the 1.8% downward assay trend observed at 18 months for Pantoprazole Sodium DR Tablets 40 mg reflects analytical variability and not true product degradation, on the basis of method variability characterization, trend rate projection against the 24-month shelf-life specification, and review of historical assay results.
Authorizing Individual
Dr. Linda Walsh, Senior Director of Stability and Analytical Sciences
Authority Basis
STAB-AUTH-001 §4.2 — designated authority for OOT no-impact conclusion authorization on commercial stability protocols
Evidence Reviewed
OOT-2024-0019 · Method validation MV-Pantoprazole-2022 · Historical assay data 2020-2024 · Trend rate projection TRP-2024-0019 · Shelf-life specification SLS-Pantoprazole · 21-month timepoint result
Alternatives Eliminated
Early-stage degradation pattern · Packaging integrity issue · Container-closure compromise · Formulation drift · Reference standard drift — each evaluated against documented evidence
Authorization Timestamp
November 12, 2024 — 11:30 EST
Regulatory Framework
21 CFR 211.166 · ICH Q1A(R2) · ICH Q1E · 21 CFR 211.137
— Continued in the complete file —
Inspection Exposure Snapshot

Want the 483 observation language for your records?

The exact citation language an investigator uses when this gap appears. Sent to your inbox. Useful as a reference. No follow-up sales sequence.

No spam · Unsubscribe anytime

Continued · Part 03 of 03

The structure is clear. The example is published. The record itself is in the complete file.

See the complete authorization record.

A completed reference DDR for the Vancomycin scenario. The blank template applied to your facility. The evidence checklist that closes the gap before inspection begins.

Show Me the Complete File →
✓ Free to read · Three commitment levels available

Used by Quality and Validation leaders preparing for FDA and EMA inspections. Built around 21 CFR 211.192 and ICH Q9.